Skip to main content
Midas Edge

Edgewise Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

EWTX$45.04+15.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 5. Other Information

Director and Officer Trading Arrangements

During the last fiscal quarter, the following directors and “officers,” as defined in Rule 16a-1(f) of the Exchange Act, terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in item 408 of Regulation S-K:

On April 3, 2025, Marc Semigran, our former Chief Development Officer, terminated a Rule 10b5-1 trading arrangement providing for the sale from time to time of up to 75,000 shares of our common stock. The trading arrangement was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement was until December 31, 2025, or earlier if all transactions under the trading arrangement were completed.

On June 11, 2025, Alan Russell, our Chief Scientific Officer and Director, terminated a Rule 10b5-1 trading arrangement providing for the sale from time to time of up to 300,000 shares of our common stock. The trading arrangement was intended to satisfy the affirmative defense in Rule 10b5-1(c). The duration of the trading arrangement was until September 30, 2025, or earlier if all transactions under the trading arrangement were completed.

No other directors or “officers,” as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in item 408 of Regulation S-K, during the last fiscal quarter.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.